CA2361578A1 - Method for the prevention or reduction of cardiovascular events associated with coronary intervention - Google Patents

Method for the prevention or reduction of cardiovascular events associated with coronary intervention Download PDF

Info

Publication number
CA2361578A1
CA2361578A1 CA002361578A CA2361578A CA2361578A1 CA 2361578 A1 CA2361578 A1 CA 2361578A1 CA 002361578 A CA002361578 A CA 002361578A CA 2361578 A CA2361578 A CA 2361578A CA 2361578 A1 CA2361578 A1 CA 2361578A1
Authority
CA
Canada
Prior art keywords
coronary intervention
pharmaceutically acceptable
acceptable salt
dimethoxycinnamoyl
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361578A
Other languages
English (en)
French (fr)
Inventor
David C. U'prichard
Jeffrey R. Granett
Neil H. Shusterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361578A1 publication Critical patent/CA2361578A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002361578A 1999-02-03 2000-02-02 Method for the prevention or reduction of cardiovascular events associated with coronary intervention Abandoned CA2361578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11846399P 1999-02-03 1999-02-03
US60/118,463 1999-02-03
PCT/US2000/002611 WO2000045810A1 (en) 1999-02-03 2000-02-02 Method for the prevention or reduction of cardiovascular events associated with coronary intervention

Publications (1)

Publication Number Publication Date
CA2361578A1 true CA2361578A1 (en) 2000-08-10

Family

ID=22378760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361578A Abandoned CA2361578A1 (en) 1999-02-03 2000-02-02 Method for the prevention or reduction of cardiovascular events associated with coronary intervention

Country Status (17)

Country Link
EP (1) EP1180027A4 (ko)
JP (1) JP2002536326A (ko)
KR (1) KR20010101933A (ko)
CN (1) CN1338930A (ko)
AR (1) AR022475A1 (ko)
AU (1) AU2978500A (ko)
BR (1) BR0007901A (ko)
CA (1) CA2361578A1 (ko)
CO (1) CO5160246A1 (ko)
HU (1) HUP0200148A3 (ko)
IL (1) IL144719A0 (ko)
MX (1) MXPA01007833A (ko)
NO (1) NO20013789L (ko)
PL (1) PL349926A1 (ko)
TR (1) TR200102262T2 (ko)
WO (1) WO2000045810A1 (ko)
ZA (1) ZA200106297B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
EP0855387A4 (en) * 1995-09-07 1999-09-15 Kissei Pharmaceutical 2-ACYLAMINOBENZAMIDE DERIVATIVES, PREVENTIVE AND REMEDY AGAINST DISEASES CAUSED BY OVERMULTIPLICATION OF INTIMA VASCULAR CELLS
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
NO20013789D0 (no) 2001-08-02
EP1180027A4 (en) 2004-11-17
CN1338930A (zh) 2002-03-06
CO5160246A1 (es) 2002-05-30
KR20010101933A (ko) 2001-11-15
PL349926A1 (en) 2002-10-21
IL144719A0 (en) 2002-06-30
TR200102262T2 (tr) 2002-02-21
HUP0200148A2 (hu) 2002-05-29
MXPA01007833A (es) 2002-06-21
EP1180027A1 (en) 2002-02-20
AR022475A1 (es) 2002-09-04
HUP0200148A3 (en) 2003-06-30
AU2978500A (en) 2000-08-25
JP2002536326A (ja) 2002-10-29
BR0007901A (pt) 2001-10-30
WO2000045810A1 (en) 2000-08-10
ZA200106297B (en) 2002-07-31
NO20013789L (no) 2001-09-28

Similar Documents

Publication Publication Date Title
CA2106172C (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment of restenosis associated with coronary intervention
TW389696B (en) Accelerated release composition containing bromocriptine
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
KR19980064024A (ko) 약학 조성물
HU217833B (hu) Eljárás difenil-butil-piperazin-karboxamidokat tartalmazó, mértéktelen szerfogyasztásból eredő betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
SK287972B6 (sk) Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof
WO2005084392A2 (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
BG99164A (bg) Антиисхемично лекарствено средство
WO2004066998A1 (ja) 安定な経口用固形医薬組成物
GB2393181A (en) Amorphous clopidogrel
AU2007234917B2 (en) Renin inhibitors for the treatment of hypertension
CA2361578A1 (en) Method for the prevention or reduction of cardiovascular events associated with coronary intervention
WO2001062241A1 (en) Method for the prevention or reduction of vascular access dysfunction
CA2361581A1 (en) Method for the prevention or reduction of cariovascular events associated with coronary intervention
JP3150642B2 (ja) 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法
WO2003043632A2 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
WO2019241495A1 (en) Pharmaceutical composition and method for acute on chronic liver failure
IE71022B1 (en) Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamides containing preparation and stabilizing method therefor
WO2001097798A1 (en) Method for the prevention or reduction of cardiovascular events associated with coronary intervention
US20080139668A1 (en) Pharmaceutical composition for obovatol for the prevention and treatment of restenosis
AU627277B2 (en) A method of treatment or prevention of post-ptca restenosis by post-ptca restenosis inhibitor
WO2002056941A2 (en) Method for the treatment of peripheral vascular disease
MXPA05005078A (en) Pharmaceutical composition having a higher ciprofloxacin bioavailability

Legal Events

Date Code Title Description
FZDE Discontinued